10 results about "Alendronic acid" patented technology

The invention relates to the technical field of biomedical materials, in particular to an alendronate-modified ZIF-8 encapsulated TPP-carbon dot bone targeting nano-material and a preparation method and application thereof.The alendronate-modified ZIF-8 serves as a carrier, TPP-modified carbon dots are encapsulated in the carrier, citric acid, urea and cerium salt serve as raw materials of the TPP-modified carbon dots, and the alendronate-modified ZIF-8 encapsulated TPP-carbon dot bone targeting nano-material is prepared through a one-step method. After cerium-doped carbon quantum dots are synthesized through a hydrothermal method, TPP is grafted through an amide method, alendronate endows the material with a bone targeting function, and TPP modified carbon dots endow the material with antioxidant and mitochondrial targeting functions. According to the invention, the bone targeting property is excellent, and bone focuses are efficiently enriched; the anti-oxidation and anti-inflammatory capacities are high, and the infected microenvironment can be improved; zIF-8 packaging is stable, and functional components can be controllably released; multiple components cooperate to promote bone repair, accumulation of non-target organs is little, and the composition is safe, reliable and suitable for treatment of various bone-related diseases.

The invention discloses a preparation method and application of polydopamine-mediated uniformly phosphorylated nano onion carbon, nano onion carbon prepared in a laboratory is used as a raw material, and carboxylated nano onion carbon (C-CNOs) is generated by a concentrated nitric acid / sulfuric acid mixed acid oxidation reaction; the preparation method comprises the following steps: obtaining nano onion carbon (D-CNOs) uniformly wrapped by polydopamine by adopting a dopamine polymerization deposition method; then, alendronic acid and D-CNOs are subjected to a Michael addition reaction, and uniformly phosphorylated CNOs (PD-CNOs) are prepared; the preparation process is simple, and the obtained product has a typical onion-like layered structure, is uniform in size, can be widely applied to the field of ion exchange materials as a functional nanofiller, and is particularly suitable for modification and enhancement of polymer electrolyte membranes.

Formulation of nanoparticles of calcium phosphate, preferably hydroxyapatite, said nanoparticles being modified with lecithin, preferably phosphatidylcholine, said formulation having an enhanced cellular uptake and being a carrier for bisphosphonate, characterised in that bisphosphonate is selected from the group of bisphosphonate drugs approved for medical use, the group comprising alendronate and zoledronate, bisphosphonate is encapsulated in calcium phosphate nanoparticles in an amount up to 40% by mass, and the nanoparticles are less than 200 mn in size. Method of obtaining said formulation, comprising the steps: a. dissolving Ca(N03)2. 4H2O in a lecithin solution, b. dissolving (NH4)2HP04 in a bisphosphonate solution, c. adjusting the pH of the solution resulting from step a. and of the solution resulting from step b. to the value of 10, d. mixing the solutions from step c. in a reactor to obtain a suspension, e. centrifuging the suspension from step d. to obtain precipitate, f. purifying the precipitate from step e. by rinsing it four times with ultrapure water and centrifuging, g. drying the precipitate from step f. at 50° C. for 12-24 h, h. grinding the precipitate from step g. in a ball mill for 10 minutes at a speed of 150 rpm, wherein step d. is carried out in a continuous or batch reactor.

This invention belongs to the field of biomedical technology, and specifically relates to an alendronate magnesium nanoparticle formulation and its application in metabolic-associated fatty liver disease (MAFLD). The alendronate magnesium (MgALN) nanoparticle formulation of this invention is formed by the coordination of alendronate sodium and magnesium ions. The prepared MgALN nanoparticle formulation has an average particle size of approximately 452 nm, exhibiting good dispersibility and stability, achieving highly efficient targeted enrichment of the drug in the liver, and significantly improving the drug's retention time and local concentration in the liver. This formulation effectively inhibits lipid accumulation in hepatocytes, improves the pathological phenotype of fatty liver in mice induced by a high-fat diet, and has no significant cytotoxicity or systemic toxicity in vivo. This invention solves the problems of insufficient liver targeting, low bioavailability, and limited efficacy of traditional alendronate sodium in treating MAFLD, providing a novel and highly effective targeted drug for the clinical treatment of MAFLD, and has significant clinical application value.

This invention belongs to the field of medical materials technology and discloses a titanium implant material with both anti-infection and bone integration promoting functions, as well as its preparation method. The titanium implant material includes a titanium material with calcium-copper ion-containing surface, and a coating attached to the surface of the calcium-copper ion-containing titanium material. The coating includes glucose oxidase-modified hollow manganese dioxide nanoparticles and alendronate-modified hyaluronic acid. The titanium implant material of this invention possesses both anti-infection and bone integration promoting functions, and also exhibits good anti-inflammatory effects.

The application discloses a CD301b + EXO and a preparation method thereof, and a bone-targeting microsphere loaded with the CD301b + EXO and an application thereof. The bone-targeting microsphere loaded with the CD301b + EXO is modified by a functional component of alendronate, is endowed with excellent bone targeting capability, can significantly improve the enrichment and retention of the exosome in a bone defect area, and realizes sustained and controllable release in a bone defect environment. The application fully plays the triple repair function of the CD301b + EXO, and realizes the synergistic promotion of the whole bone healing process by combining the bone targeting and slow-release characteristics of the microsphere, significantly improves the repair efficiency and quality, and has high clinical transformation value.

The invention relates to the technical field of polymer drug carriers, in particular to a polyamino acid nano-carrier, a polyamino acid nano-particle and a preparation method of the polyamino acid nano-carrier and the polyamino acid nano-particle. The polyamino acid nanoparticles provided by the invention can inhibit generation of M2 macrophages by removing active oxygen and promote M1 type polarization of the macrophages by releasing an immunologic stimulant so as to be used for immunotherapy of osteosarcoma. In addition, the alendronate component in the polyamino acid nanoparticles can inhibit osteoclast activity on the basis of improving tumor targeting, so that bone destruction is relieved. Tests show that after the polyamino acid nanoparticles provided by the invention are intravenously injected into a mouse with osteosarcoma, the progress of in-situ osteosarcoma is obviously inhibited. Therefore, the immunotherapy started by the polyamino acid nanoparticles capable of regulating and controlling the polarization of the macrophages, provided by the invention, provides a promising alternative scheme for clinical osteosarcoma treatment.

The invention discloses sustained-release oral powder for treating osteoporosis and a preparation method of the sustained-release oral powder. The sustained-release oral powder comprises 2 parts of a supramolecular metal organic framework material sMOF, 0.8-1.0 part of microcrystalline cellulose and 0.1-0.2 part of magnesium stearate. Wherein the supramolecular metal organic framework material sMOF is formed by coordination self-assembly of Sr < 2 + >, Mg < 2 + >, alendronate (ALN), 1, 6-fructose diphosphate sodium salt (FDP) and casein phosphopeptides (CPP). The powder has excellent treatment effect, biocompatibility and slow release characteristic, can effectively promote osteoblast differentiation, inhibit osteoclast activity and reverse bone mineral density decline, and is suitable for treatment of bone diseases such as osteoporosis and fracture.

The invention provides a bone targeting nucleic acid drug delivery system and a preparation method and application thereof, and is characterized in that active components of the bone targeting nucleic acid drug delivery system comprise strong electropositive lactoferrin nanoparticles for loading nucleic acid, bone targeting molecules and a nucleic acid drug, according to the nucleic acid-loaded strong electropositive lactoferrin nanoparticle, the surface of a lactoferrin nanoparticle is covalently modified with a polymerizable acryloyl group, the bone targeting molecule is alendronate, and the surface of the alendronate is covalently modified with a polymerizable acryloyl group. The nucleic acid medicine comprises one or more of small interfering ribonucleic acid, micro ribonucleic acid and nucleic acid aptamers with a bone resorption inhibiting function. The bone targeting nucleic acid drug delivery system is prepared by an in-situ free radical polymerization method. The prepared bone targeted delivery system can be efficiently delivered to bone tissue in a targeted mode, the function of osteoclasts can be regulated and controlled, the osteoinflammation microenvironment is improved by regulating immune balance, bone regeneration of osteoporosis diseases is effectively promoted, and the bone targeted delivery system can be widely applied to treatment of orthopedic diseases.

The invention discloses a CD301b < + >-EXO, a preparation method of the CD301b < + >-EXO, a CD301b < + >-EXO loaded bone targeting microsphere as well as a preparation method and application of the CD301b < + >-EXO loaded bone targeting microsphere. The CD301b < + >-EXO loaded bone targeting microsphere adopts an alendronate modified functional component, is endowed with excellent bone targeting ability, can significantly improve the enrichment and retention of exosomes in a bone defect area, and realizes continuous controllable release in a bone defect environment. According to the invention, the triple repair function of CD301b < + >-EXO is fully exerted, and the bone targeting and slow release characteristics of the microspheres are combined, so that the synergistic promotion of the whole bone healing process is realized, the repair efficiency and quality are remarkably improved, and the clinical transformation value is very high.